# R1 Clinical-Safety Review — serrated_polyposis_syndrome

VERDICT: APPROVE

goldens changed: no (intended: n/a — KB narrative content, no engine/rule/test outputs touched)

Adversarial verdict file: NOT PRESENT (.verdict.md absent). No still-present flagged issues to block on.

## 1. Safety
No unsafe, misleading, or harmful-if-followed statement found.
- Correctly frames SPS as a polyp-burden / cancer-risk problem managed by endoscopic
  surveillance + clearance, not systemic cytotoxic therapy — accurate.
- Surgery explicitly positioned as reserved (uncontrollable polyp burden or established cancer),
  NOT prophylactic-for-all — this is the safe, correct distinction from FAP-type syndromes; avoids
  the harm of over-recommending colectomy.
- No absolute/directive claims that overstep decision-support; timing deferred to guidelines.

## 2. Grounding (DeVita / NCCN standard of care)
Consistent. The draft is unusually transparent that DeVita has no dedicated SPS chapter and
explicitly labels every extrapolation as "general oncology standard, not from DeVita's section."
DeVita-attributed claims checked:
- Serrated neoplasia pathway as a distinct route to CRC via accumulating serrated lesions (BRAF,
  sessile serrated lesions, right-sided MSI-high) — genuinely DeVita molecular-genetics content, correctly attributed.
- Acquired MMR deficiency via BRAF mutation + CpG-island promoter methylation — DeVita-consistent.
- The surveillance-with-complete-clearance GOAL is framed as "grounded in DeVita's description of
  the serrated pathway," with interval timing explicitly deferred to society/NCCN guidance. This is
  a defensible framing (pathway = DeVita; management cadence = guidelines), not a misattribution of a
  management algorithm to DeVita. No fabricated or outdated regimen. No DeVita citation for a claim
  not in DeVita.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, numbered schedule, or fixed interval value. "Fluoropyrimidine-based
chemotherapy" and "biologic/immune checkpoint therapy" are named only at drug-class level. Clean.

## 4. Scope
Appropriately hedged as decision-support: defers exact surveillance intervals and systemic
sequencing to current NCCN/society guidance, flags residual content for manual clinician sourcing,
and avoids directive commands. Refer/monitoring sections are appropriate.

## Advisory (non-blocking)
- Lines 24-26: the "complete endoscopic clearance" objective leans on DeVita's pathway description
  as its grounding. Consider relabelling the clearance goal itself as general/society standard
  (as done elsewhere) to keep the DeVita attribution strictly to the pathway biology. Cosmetic;
  does not rise to a mis-sourcing block.

Chaining: not AI-assisted generation flagged for stewardmd-ai-reviewer here; no PHI touched
(no stewardmd-security-reviewer needed).
